Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKCPT
- Development stage
- Phase 3
- Lead developer
- SK Chemicals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
SKCPT (also known as SKI 306X) is a botanical drug and symptomatic slow-acting drug for osteoarthritis (SYSADOA) developed by SK Chemicals. It is a purified herbal extract formulated from three traditional medicinal plants: *Clematis mandshurica*, *Trichosanthes kirilowii*, and *Prunella vulgaris*. SKCPT exerts anti-inflammatory and cartilage-protective effects by inhibiting glycosaminoglycan degradation and suppressing catabolic gene expression in human osteoarthritis chondrocytes. In clinical trials, SKCPT has demonstrated non-inferiority to the NSAID celecoxib in reducing pain and improving joint function in patients with knee osteoarthritis, while offering a safety profile that may avoid the long-term gastrointestinal and cardiovascular side effects associated with traditional NSAIDs.
- Brand names
- Joins
- Other names
- Clematis mandshurica + Trichosanthes kirilowii + Prunella vulgaris extract
Beyond the preview
Go deeper on SKCPT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKCPT.